Synonym
Ciprokiren; UNII-K259Z4O1B3
IUPAC/Chemical Name
(alphaS)-N-((1S,2R,3S)-1-(Cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((alphaS)-alpha-(((1-methyl-1-(morpholinocarbonyl)ethyl)sulfonyl)methyl)hydrocinnamamido)imidazole-4-propionamide
InChi Key
PODHJNNUGIBMOP-HOQQKOLYSA-N
InChi Code
InChI=1S/C37H55N5O8S/c1-37(2,36(47)42-15-17-50-18-16-42)51(48,49)23-28(19-25-9-5-3-6-10-25)34(45)41-31(21-29-22-38-24-39-29)35(46)40-30(20-26-11-7-4-8-12-26)33(44)32(43)27-13-14-27/h3,5-6,9-10,22,24,26-28,30-33,43-44H,4,7-8,11-21,23H2,1-2H3,(H,38,39)(H,40,46)(H,41,45)/t28-,30+,31+,32+,33-/m1/s1
SMILES Code
O=C(N[C@@H](CC1CCCCC1)[C@@H](O)[C@H](C2CC2)O)[C@@H](NC([C@@H](CS(=O)(C(C(N3CCOCC3)=O)(C)C)=O)CC4=CC=CC=C4)=O)CC5=CNC=N5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
729.93
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Clozel JP, Véniant M, Sprecher U, Fischli W. Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs. J Cardiovasc Pharmacol. 1995 Oct;26(4):674-7. doi: 10.1097/00005344-199510000-00025. PMID: 8569232.
2: Fischli W, Clozel JP, Breu V, Buchmann S, Mathews S, Stadler H, Vieira E, Wostl W. Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension. 1994 Aug;24(2):163-9. doi: 10.1161/01.hyp.24.2.163. PMID: 8039839.
3: Barbe F, Su JB, Guyene TT, Crozatier B, Ménard J, Hittinger L. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. Am J Physiol. 1996 Jun;270(6 Pt 2):H1985-92. doi: 10.1152/ajpheart.1996.270.6.H1985. PMID: 8764248.
4: Su JB, Barbe F, Houel R, Guyene TT, Crozatier B, Hittinger L. Preserved vasodilator effect of bradykinin in dogs with heart failure. Circulation. 1998 Dec 22-29;98(25):2911-8. doi: 10.1161/01.cir.98.25.2911. PMID: 9860795.
5: Costerousse O, Allegrini J, Clozel JP, Ménard J, Alhenc-Gelas F. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther. 1998 Mar;284(3):1180-7. PMID: 9495881.
6: Clozel JP, Hess P, Schietinger K, Breu V, Fischli W, Baumgartner HR. Major role of the renin angiotensin system in the neointima formation after vascular injury in guinea pigs. Life Sci. 1994;54(6):PL87-92. doi: 10.1016/0024-3205(94)00706-3. PMID: 8295484.
7: Clozel JP, Véniant MM, Qiu C, Sprecher U, Wolfgang R, Fischli W. Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure. J Cardiovasc Pharmacol. 1999 Nov;34(5):674-82. doi: 10.1097/00005344-199911000-00008. PMID: 10547083.
8: Nekooeian AA, Ogilvie RI, Zborowska-Sluis D. Acute hemodynamic effects of drugs acting on the renin-angiotensin system in acute heart failure. Can J Cardiol. 1995 Jan;11(1):59-64. PMID: 7850666.
